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Short report
Rapid-onset clozapine-induced loss of glycaemic
control: case report
Alejandro Porras-Segovia, Amir Krivoy, Mark Horowitz, George Thomas, Mark Bolstridge, Dragos Ion and
Sukhwinder S. Shergill
Clozapine has proved to be an effective antipsychotic for the
treatment of refractory schizophrenia – characterised by the
persistence of symptoms despite optimal treatment trials with
at least two different antipsychotics at adequate dose
and duration – but its use is hampered by adverse effects.
The development of clozapine-induced diabetes is commonly
considered to arise as part of a metabolic syndrome, associated
with weight gain, and thus evolves slowly. We present the
case of an individual with refractory schizophrenia and
metformin-controlled diabetes who developed rapid-onset
insulin-dependent hyperglycaemia immediately after starting
clozapine. Given the refractory nature of his illness, the decision
was made to continue clozapine and manage the diabetes.
This case supports the existence of a more direct mechanism
by which clozapine alters glycaemic control, aside from the
more routine slow development of a metabolic syndrome.
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Clozapine is an atypical antipsychotic medication used in the
treatment of refractory schizophrenia, a condition defined as the
persistence of symptoms despite optimal treatment trials with at
least two different antipsychotics at adequate dose and duration.
Despite its unique benefits, it can also cause severe side-effects,
most notably agranulocytosis, and as a consequence its use is
strictly regulated in most countries and requires routine monitoring
of full blood count.1
Although many atypical antipsychotics, such as quetiapine or
olanzapine, can induce type 2 diabetes mellitus,2,3 clozapine is
believed to pose a higher risk of developing this metabolic disorder.4
This diabetes is conventionally thought to be associated with the
development of a broader metabolic syndrome accompanied by
an increase in obesity. However, could there be a more directly
acting mechanism influencing glycaemic control? There are
some data that suggest that antagonism ofM3 cholinergic receptors,
a feature shared by clozapine and olanzapine, can cause beta-
cell dysfunction5; whereas Smith et al6 have suggested clozapine
could directly increase the secretion of glucagon, leading to a rapid
elevation of glucose levels; and others have proposed direct
mitochondrial damage to insulin-responsive cells.7 It is of note
that there are instances of acute loss of glycaemic control reported
with other atypical antipsychotic compounds.8–10
Nevertheless, the onset of diabetes mellitus poses a
serious challenge to practitioners and is a significant reason for
clozapine discontinuation11–13; however, given the lack of alter-
native treatments, there is an argument for aggressive treatment
of the diabetes mellitus to allow clozapine to be continued or
reinitiated.12
Here, we present the case of an individual with refractory
schizophrenia who developed rapid-onset insulin dependence at
the commencement of his clozapine therapy – too short a time
frame for an acute worsening of a metabolic syndrome, implicat-
ing a direct mechanism for rapid loss of glycaemic control – and
in whom diabetes was treated successfully without discontinuing
clozapine.
Case presentation
Mr A is a 48-year-old male of African origin with a diagnosis
of treatment-resistant paranoid schizophrenia. He was transferred
to the National Psychosis Unit, a tertiary referral in-patient
service, for re-titration of clozapine after cessation because of
side-effects.
Mr A was first known to UK psychiatric services in 1993, the
year of his arrival in this country, at the age of 25. He presented
with paranoid and grandiose delusions, as well as auditory
hallucinations. His symptoms persisted despite treatment and
were often associated with violent behaviour, requiring several
involuntary admissions to psychiatric wards over the years.
Various medications were trialled, including olanzapine (15 mg
daily for approximately 4 years), risperidone (up to 9 mg daily for
approximately 5 years), paliperidone palmitate (150 mg monthly
for approximately 2 years), flupentixol depot (40 mg three times
a week for approximately 10 years) and clozapine (up to 400 mg
a day for 2 non-consecutive years).
Clozapine proved to be the most effective treatment for
symptom control, but was stopped on two occasions after a rapid
loss of glycaemic control, requiring insulin treatment.
Shortly after both clozapine cessations, his diabetes had
improved to the point that insulin administration was no longer
necessary, and his glycaemic control was maintained with met‐
formin 1 g twice daily. He also suffered from hypertension
(average blood pressure: 165/101mmHg) and hypercholesterolemia
(low-density lipoprotein (LDL) levels: 270 mg/dL). He was a
one-pack-per-day smoker and was overweight (body mass index
(BMI) of 28.7 at the time of admission).
On admission to the unit, Mr A was irritable, often shouting
and at times intimidating towards staff. He presented with paranoid
and grandiose delusions and was grossly thought-disordered.
Perceptual abnormalities were suspected, as he was often observed
responding to unseen stimuli.
The antipsychotic treatment on admission – risperidone – was
switched to lurasidone because of a more benign metabolic
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side-effect profile.14 However, this was not effective in controlling
symptoms and was later changed to amisulpride, which also
produced no improvement in his mental state. Finally, given the
lack of any progress, it was decided to commence clozapine.
At this stage, it was decided to seek collaboration with the local
endocrinologists to safely manage the risk of emergent loss of
glycaemic control. The individual’s fasting blood glucose levels
were measured before commencing clozapine to establish a baseline
(4–6 mmol/L). Despite using a slow-titration approach, 6 days after
commencing clozapine his glucose levels started to increase linearly
(see Fig. 1). HbA1c values also increased over a short period of time
(from 7.3 to 12.1% in the course of 2 months). Interestingly,
clozapine dose was only 100 mg (serum levels: 65 ng/ml) at the time
his glucose levels were becoming elevated. This elevation was
associated with the increase of clozapine dose.
He was commenced on insulin therapy, at an initial dose of four
units of fast-acting insulin once daily. Clozapine was slowly titrated
upwards in increments of 25 mg, once the blood glucose levels had
stabilised for 2–3 days, until a dose of 700 mg/day (serum levels:
460 ng/ml) was reached. The dose of insulin was increased slowly
until he achieved glycaemic control while being treated with 52 units
of medium-acting insulin twice daily. He continued taking metformin
1 g twice a day and commenced on a 2 mg weekly injection of
long-acting exenatide – a glucagon-like peptide-1 agonist.
The individual’s mental state improved considerably during his
admission. His thought and speech disorders were ameliorated,
although still noticeable in a prolonged conversation. Perceptual
abnormalities were no longer noted, although he continued to
experience paranoid delusions to a lower degree. He started to
engage in art activities, showing some talent in this area, and
retained a calm demeanour for increasing periods of time. He
gained partial insight, identifying the need for medications and
follow-up. His weight increased slightly (from a BMI of 28.7 to 28.9)
and his smoking was reduced by half.
After 5 months of treatment, the individual’s psychotic
symptoms were significantly reduced and glycaemic control was
stable. He was discharged from hospital, with his care taken over
by his local mental health team; his diabetes care was managed
by his general practitioner with specialist input from the
endocrinologists.
Discussion
This case supports the existence of a direct mechanism by which
clozapine may alter the glycaemic control pathways. Our patient
developed rapid loss of glycaemic control within days of starting
the medication, meaning it was unlikely to be caused by inter‐
mediate factors such as increased appetite, weight gain or insulin
resistance. He was not taking any other medication likely to cause
hyperglycaemia. Clozapine produced a linear dose-related increase
in glycaemic levels during the first 2 months of treatment, which
from 400 mg onwards seemed to reach a plateau. Although there is
an apparent dose-dependence, treatment duration-dependence as a
contributing factor cannot be excluded.
Given the lack of any effective symptom management
with other antipsychotic medication and the complexity of the
clinical presentation, it was decided to continue clozapine,
but to manage the hyperglycaemia while continuing with the
medication.
To do this, we followed the Maudsley prescribing guidelines’
recommendations for treatment of antipsychotic-related dia-
betes.15 Of equal importance was the collaboration with a clinical
pharmacist specialising in mental health and with endocrinolo-
gists, who oversaw the individual’s treatment. This approach
requires vigorous baseline and follow-up monitoring of glucose
levels and HbA1c values, slower clozapine titration schedule, and
full control of glycaemic levels before every dose increase of
clozapine.
Clinicians should also monitor weight gain and lipid levels, as
well as considering other potential risk factors for diabetes5; one
such factor being African ethnicity, which some studies suggest is
associated with a higher risk of diabetes mellitus.16 There are
several pharmacological treatment options for diabetes mellitus; in
this case, we used insulin and long-acting exenatide – a recently
introduced glucagon-like peptide-1 (GLP-1) agonist that requires
a weekly injection – added to his existing metformin. The reason
for using exenatide is based on recent research, which suggests
that hyposecretion of incretin hormone GLP-1 may partially
account for the rapid diabetogenic effect of clozapine.17
Clearly, it may still be necessary to discontinue clozapine in
the event of a severe diabetes mellitus complication, such as
ketoacidosis.12
Our case illustrates the successful management of insulin
dependence in an individual with refractory schizophrenia and
diabetes mellitus previously controlled by metformin. In people
with refractory schizophrenia, the effectiveness of clozapine must
be balanced against the risks posed by side-effects. In such cases, a
personalised plan is required to support the aggressive treatment
of the iatrogenic side-effects while continuing clozapine treatment.
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Fig. 1 Correlation of clozapine daily dose with fasting blood sugar and HbA1c levels, prior to the administration of insulin.
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